Skip to main content
Rajesh Pahwa, MD, Neurology, Kansas City, KS

RajeshPahwaMD

Neurology Kansas City, KS

Movement Disorder

Professor, Neurology, University Kansas School of Medicine

Dr. Pahwa is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Pahwa's full profile

Already have an account?

  • Office

    3599 Rainbow Blvd
    Kansas City, KS 66160
    Phone+1 913-588-6970
    Fax+1 913-535-2103

Summary

  • Dr. Rajesh Pahwa is a neurologist in Kansas City, KS and is affiliated with The University of Kansas Health System. He received his medical degree from Seth G.S. Medical College and has been in practice 34 years. He specializes in movement disorder and is experienced in parkinson's disease, deep brain stimulation and clinical trials.

Education & Training

  • University of Kansas School of Medicine
    University of Kansas School of MedicineResidency, Neurology, 1991 - 1992
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Neurology, 1987 - 1991
  • Seth G.S. Medical College
    Seth G.S. Medical CollegeClass of 1983

Certifications & Licensure

  • KS State Medical License
    KS State Medical License 1991 - 2025
  • MO State Medical License
    MO State Medical License 2021 - 2025
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Wren Builds Out Scientific Advisory Board for Neurodegenerative Diseases
    Wren Builds Out Scientific Advisory Board for Neurodegenerative DiseasesJanuary 4th, 2023
  • Dosing Begins in Phase 1 Trial of AP-472, for Dyskinesia with Levodopa
    Dosing Begins in Phase 1 Trial of AP-472, for Dyskinesia with LevodopaOctober 7th, 2021
  • World Parkinson Coalition Welcomes Five New Directors
    World Parkinson Coalition Welcomes Five New DirectorsJanuary 30th, 2020
  • Join now to see all

Committees

  • Member, Parkinson's Disease Practice Guidelines Committee

Professional Memberships